Evidence map›Paper›PMID 25887484›Full record

ReviewBMC immunology2015

What is infectiveness and how is it involved in infection and immunity?

Liise-anne Pirofski, Arturo Casadevall

Open access · goldAbstract readHistorical ArticleReview
In one paragraph

Review in BMC immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Virulence factors released by extracellular vesicles fromFrontiers in cellular and infection microbiology · 2025
    Review
  3. Article
  4. Review
  5. Review
  6. Obligate anaerobes are abundant in human necrotizing soft tissue infection samples - a metagenomics analysis.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2019
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Liise-anne PirofskiDivision of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Room 610 Belfer Building, 1300 Morris Park Avenue, Bronx, NY, 10461, USA. l.pirofski@einstein.yu.edu.
Arturo CasadevallDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA. arturo.casadevall@einstein.yu.edu.
Albert Einstein College of Medicine · USMontefiore Medical Center · US

Funding

Synergy of Host Defense Mechanisms in the LungR01HL059842 · NHLBI · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 1997 to 2023
$7.4M
Biology of Fungal MelaninR01AI052733 · NIAID · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 2003 to 2019
$6.6M
PROTECTIVE ANTIBODIES FOR CRYPTOCOCCAL INFECTIONSR01AI033774 · NIAID · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 1994 to 2014
$5.6M
Molecular Characterization of C. neoformans AntibodiesR37AI033142 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CASADEVALL, ARTURO · 2007 to 2016
$3.9M
B cell subsets and immunity to cryptococcosisR01AI097096 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI PIROFSKI, LIISE-ANNE · 2012 to 2016
$2.7M
Effects of aging and HIV infection on the response to pneumococcal vaccineR01AG045044 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI PIROFSKI, LIISE-ANNE · 2014 to 2018
$2.5M
Antibody immunity to serotype 3 Streptococcus pneumoniaeR56AI104234 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI PIROFSKI, LIISE-ANNE · 2013 to 2013
$407k
NHLBI NIH HHS R01 HL059842NHLBI NIH HHS R01HL059842NIAID NIH HHS R01 AI033774NIAID NIH HHS R01AI033774NIAID NIH HHS R01 AI052733NIAID NIH HHS R01AI052733NIAID NIH HHS R01 AI097096NIAID NIH HHS R01AI097096NIAID NIH HHS R37 AI033142NIAID NIH HHS R37AI033142NIAID NIH HHS R56 AI104234NIAID NIH HHS R56AI104234NIA NIH HHS R01 AG045044NIA NIH HHS R01AG045044
6 · The paper itself

Abstract

Proof of the Germ theory of disease and acceptance of Koch's postulates in the late 1890's launched the fields of microbial pathogenesis and infectious diseases and provided the conceptual framework that has guided thought and research in these fields. A central tenet that emerged from studies with microbes that fulfilled Koch's postulates was that microbes that caused disease had characteristics that allowed them to do so, with the corollary that microbes that did not cause disease lacked disease-causing determinants. This observation, which held true for many diseases that were known to cause disease in the late 19(th) century, such as toxin-producing and encapsulated bacteria, led to the view that the ability to cause disease rested with microbes and reflected the activity of specific determinants, or virulence factors. With the dawn of the 20(th) century, efforts to neutralize virulence factors were under development and ultimately translated into anti-microbial therapy in the form of antibodies targeted to toxins and polysaccharide capsules. However, the 20(th) century progressed, antibiotics were identified and developed as therapy for infectious diseases while other medical advances, such as specialized surgeries, intensive care units, intravenous catheters, and cytotoxic chemotherapy became commonplace in resourced nations. An unintended consequence of many of these advances was that they resulted in immune impairment. Similarly, HIV/AIDS, which emerged in the late 1970's also produced profound immune impairment. Unexpectedly, the prevailing view that microbes were the sole perpetrators of virulence was untenable. Microbes that were rarely if ever associated with disease emerged as major causes of disease in people with impaired immunity. This phenomenon revealed that available explanations for microbial infectiveness and virulence were flawed. In this review, we discuss the question 'what is infectiveness' based on the tenets of the Damage-response framework.

Indexed as

ImmunityAnimalsAnti-Bacterial AgentsAnti-Infective AgentsHistory, 19th CenturyHistory, 20th CenturyHistory, 21st CenturyHumansInfectionsMicrobiologyReceptors, Pattern RecognitionVirulenceAnti-Bacterial AgentsAnti-Infective AgentsReceptors, Pattern Recognition

Identifiers

PMID25887484
PMCPMC4374184
OpenAlexW1990281478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.